Dynavax Technologies reported $61.33M in Cost of Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
TG Therapeutics TGTX:US USD 2K 21K
Abbvie ABBV:US USD 5.02B 880M
Adma Biologics ADMA:US USD 31.43M 5.3M
Agenus AGEN:US USD 308K 1.72M
Amgen AMGN:US USD 1.59B 78M
Astrazeneca AZN:US USD 2.12B 214M
AstraZeneca AZN:LN USD 2.12B 214M
Biogen BIIB:US USD 469.5M 14.5M
Biomarin Pharmaceutical BMRN:US USD 116.29M 6.84M
Bristol Myers Squibb BMY:US USD 2.35B 324M
Chimerix CMRX:US USD 333K 333K
Dynavax Technologies DVAX:US USD 61.33M 22.04M
Gilead Sciences GILD:US USD 1.4B 47M
Glaxosmithkline GSK:US GBP 2.39B 250M
Merk MRK:US USD 3.43B 715M
Nektar Therapeutics NKTR:US USD 4.97M 143K
Neurocrine Biosciences NBIX:US USD 6.1M 1.3M
Novartis NOVN:VX USD 3.66B 92M
Pfizer PFE:US USD 6.09B 2.58B
Regeneron Pharmaceuticals REGN:US USD 317.8M 20.7M
Roche Holding ROG:VX 9.56B 717M
Sarepta Therapeutics SRPT:US USD 39.95M 2.16M
Vertex Pharmaceuticals VRTX:US USD 289.4M 27.6M